Allergan Stock Price, News & Analysis (NYSE:AGN)

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan announced a quarterly dividend on Friday, July 19th. Stockholders of record on Tuesday, August 13th will be given a dividend of $0.74 per share on Friday, September 13th. This represents a $2.96 annualized dividend and a dividend yield of 1.71%. The ex-dividend date of this dividend is Monday, August 12th. View Allergan's Dividend History.

Allergan declared that its board has authorized a share repurchase plan on Tuesday, January 29th 2019, which authorizes the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 4.1% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company's board believes its stock is undervalued.

Allergan plc (NYSE:AGN) announced its quarterly earnings results on Tuesday, August, 6th. The company reported $4.38 EPS for the quarter, topping the Zacks' consensus estimate of $4.34 by $0.04. The business had revenue of $4.09 billion for the quarter, compared to analysts' expectations of $3.93 billion. Allergan had a negative net margin of 54.25% and a positive return on equity of 8.73%. Allergan's revenue for the quarter was down .8% compared to the same quarter last year. During the same period in the prior year, the company posted $4.42 earnings per share. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Allergan.

Allergan issued an update on its FY19 earnings guidance on Tuesday, August, 6th. The company provided earnings per share (EPS) guidance of >$16.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.74. The company issued revenue guidance of 15.4-15.6 billion, compared to the consensus revenue estimate of $15.32 billion.

21 Wall Street analysts have issued 12-month target prices for Allergan's stock. Their forecasts range from $144.95 to $255.00. On average, they anticipate Allergan's share price to reach $179.15 in the next year. This suggests a possible upside of 3.2% from the stock's current price. View Analyst Price Targets for Allergan.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 15 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

Media stories about AGN stock have trended somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Allergan earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Allergan.

Allergan saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 10,330,000 shares, an increase of 8.9% from the August 30th total of 9,490,000 shares. Based on an average daily trading volume, of 3,600,000 shares, the short-interest ratio is presently 2.9 days. Currently, 3.2% of the company's shares are sold short. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), AbbVie (ABBV), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG), Bayer (BAYRY) and Zoetis (ZTS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), United Rentals (URI) and Transocean (RIG).

Allergan's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.54%), Commerzbank Aktiengesellschaft FI (0.09%), Robeco Institutional Asset Management B.V. (0.06%), Metropolis Capital Ltd (0.05%), Confluence Investment Management LLC (0.05%) and CIBC Private Wealth Group LLC (0.03%). Company insiders that own Allergan stock include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Metropolis Capital Ltd, Envestnet Asset Management Inc., West Coast Financial LLC, Confluence Investment Management LLC, Meeder Asset Management Inc., Farmers & Merchants Investments Inc. and Gateway Investment Advisers LLC. View Insider Buying and Selling for Allergan.

AGN stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Commerzbank Aktiengesellschaft FI, Alpine Group USVI LLC, Alpine Group USVI LLC, Havens Advisors LLC, State of Alaska Department of Revenue, Cerebellum GP LLC and Cerebellum GP LLC. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Chris W Bodine, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $173.60.

Allergan has a market capitalization of $56.96 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]